Business Description
Tyra Biosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US90240B1061
Description
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÃ…P, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 58.96 | |||||
| Equity-to-Asset | 0.96 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -65.3 | |||||
| 3-Year EPS without NRI Growth Rate | -57.5 | |||||
| 3-Year FCF Growth Rate | -49.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.97 | |||||
| 9-Day RSI | 34.73 | |||||
| 14-Day RSI | 39.22 | |||||
| 6-1 Month Momentum % | 18.2 | |||||
| 12-1 Month Momentum % | -1.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 44.83 | |||||
| Quick Ratio | 44.83 | |||||
| Cash Ratio | 43.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -24.2 | |||||
| Shareholder Yield % | -24.23 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -28.94 | |||||
| ROA % | -27.45 | |||||
| ROIC % | -678.19 | |||||
| ROC (Joel Greenblatt) % | -1128.62 | |||||
| ROCE % | -33.04 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.15 | |||||
| Price-to-Tangible-Book | 2.15 | |||||
| EV-to-EBIT | -5.28 | |||||
| EV-to-EBITDA | -5.3 | |||||
| EV-to-FCF | -7.35 | |||||
| Price-to-Net-Current-Asset-Value | 2.23 | |||||
| Price-to-Net-Cash | 2.28 | |||||
| Earnings Yield (Greenblatt) % | -18.94 | |||||
| FCF Yield % | -7.52 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers